We are live on ! Find out more
APLS

Apellis Pharmaceuticals
APLS

Delisted

APLS was delisted on the 13th of May, 2026.

Back to rankings

99 hedge funds and large institutions have $1.03B invested in Apellis Pharmaceuticals in 2019 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 47 increasing their positions, 20 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

135% more repeat investments, than reductions

Existing positions increased: 47 | Existing positions reduced: 20

69% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 13

31% more capital invested

Capital invested by funds: $782M → $1.03B (+$243M)

8% more funds holding

Funds holding: 92 → 99 (+7)

0% more call options, than puts

Call options by funds: $1.91M | Put options by funds: $1.9M

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

7.28% less ownership

Funds ownership: 71.28% → 64% (-7.3%)

Holders
99
Holders Change
+7
Holders Change %
+7.61%
% of All Funds
2.15%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.07%
New
22
Increased
47
Reduced
20
Closed
13
Calls
$1.91M
Puts
$1.9M
Net Calls
+$5K
Net Calls Change
+$5K

Top Buyers

Rank Fund Capital Flow
1
Wellington Management Group
Wellington Management Group
Massachusetts
+$25.8M
2
BlackRock
BlackRock
New York
+$15.9M
3
State Street
State Street
Massachusetts
+$12.7M
4
Jennison Associates
Jennison Associates
New York
+$6.83M
5
Goldman Sachs
Goldman Sachs
New York
+$4.54M

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$25.2M
2
CAM
Cormorant Asset Management
Massachusetts
-$12.9M
3
VP
venBio Partners
California
-$10.7M
4
Westfield Capital Management
Westfield Capital Management
Massachusetts
-$7.11M
5
Citadel Advisors
Citadel Advisors
Florida
-$6.17M
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
26
Fidelity Investments
Massachusetts
$9.2M -$5.98K -294 -0.1%
BBA
27
Baker Bros. Advisors
New York
$7.95M – – –
FI
28
Fosun International
China
$6.42M -$651K -32,000 -11%
Charles Schwab
29
Charles Schwab
California
$6.22M +$693K +34,064 +16%
Bank of America
30
Bank of America
North Carolina
$5.1M +$176K +8,643 +4%
Bank of New York Mellon
31
Bank of New York Mellon
New York
$5.07M +$619K +30,405 +18%
Nuveen
32
Nuveen
North Carolina
$4.36M +$3.5M +172,128 New
Prudential Financial
33
Prudential Financial
New Jersey
$3.42M -$485K -23,860 -15%
AA
34
ALPS Advisors
Colorado
$3.35M -$71.1K -3,497 -3%
DekaBank Deutsche Girozentrale
35
DekaBank Deutsche Girozentrale
Germany
$3.28M +$2.73M +134,000 New
Barclays
36
Barclays
United Kingdom
$3.02M +$813K +39,983 +51%
EP
37
Eversept Partners
New York
$2.97M +$264K +12,960 +12%
Deutsche Bank
38
Deutsche Bank
Germany
$2.9M -$268K -13,152 -10%
Ameriprise
39
Ameriprise
Minnesota
$2.23M +$816K +40,112 +83%
Royal Bank of Canada
40
Royal Bank of Canada
Ontario, Canada
$2.18M -$91K -4,471 -5%
Swiss National Bank
41
Swiss National Bank
Switzerland
$2.06M +$34.6K +1,700 +2%
California State Teachers Retirement System (CalSTRS)
42
California State Teachers Retirement System (CalSTRS)
California
$1.89M +$389K +19,120 +35%
AllianceBernstein
43
AllianceBernstein
Tennessee
$1.87M +$523K +25,700 +54%
Baird Financial Group
44
Baird Financial Group
Wisconsin
$1.65M +$1.33M +65,229 New
PAMU
45
Pictet Asset Management (UK)
United Kingdom
$1.65M +$1.33M +65,194 New
Rafferty Asset Management
46
Rafferty Asset Management
New York
$1.64M +$762K +37,450 +137%
Squarepoint
47
Squarepoint
New York
$1.62M +$364K +17,889 +39%
RhumbLine Advisers
48
RhumbLine Advisers
Massachusetts
$1.57M +$318K +15,649 +34%
State of Wisconsin Investment Board
49
State of Wisconsin Investment Board
Wisconsin
$1.32M +$22.4K +1,100 +2%
SI
50
Sofinnova Investments
California
$1.26M – – –
1
2
3 4 5

APLS Hedge Fund Activity: Q2 2019 in Review

99 of the 4,605 institutional investors tracked by Wall St. Rank reported a position in Apellis Pharmaceuticals (APLS) for Q2 2019, worth a combined $1.03B — up 31% from $782M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new APLS positions and 13 closed out — a net gain of 9 holders — while 47 added to existing stakes and 20 trimmed.

The largest buyer was Wellington Management Group, adding an estimated $25.8M. The largest seller was Morgan Stanley, cutting an estimated $25.2M.

  • 99 institutional investors held Apellis Pharmaceuticals (APLS) as of Q2 2019, up from 92 in Q1 2019.
  • Funds reported $1.03B of Apellis Pharmaceuticals stock for Q2 2019, up 31% quarter-over-quarter.
  • 22 funds opened new Apellis Pharmaceuticals positions in Q2 2019 and 13 closed out, a net change of +9 holders.
  • The largest Apellis Pharmaceuticals buyer in Q2 2019 was Wellington Management Group, an estimated $25.8M added.
  • The largest Apellis Pharmaceuticals seller in Q2 2019 was Morgan Stanley, an estimated $25.2M sold.

Based on aggregated 13F filings for Q2 2019.